Complete patient clearance is often required by regulatory agencies for the approval of treatments for actinic keratosis (AK). However, an increasing number of clinicians have challenged the use of this measure in clinical practice and its interpretation. It has been argued that complete patient clearance often underestimates the clinical benefit of a drug and is influenced by a number of key confounding factors, such as number and distribution of lesions, at baseline. Lesions response rate is one alternative which has been suggested as more relevant due to its applicability to clinical practice and closer reflection of the clinical value of the drug. This paper provides an updated perspective on the topic and details the current thinking on the role of complete clearance and lesion response rate in the context of AK.
clearance as a result of therapy, followed by the recurrence of lesions continuously over time [1] .
The primary goal of AK therapy is the clearance of lesions to reduce the risk of further progression into SCC [3] . In addition,
there is a growing consensus and recognition among clinicians, regarding the significance of actinic field damage, its relevance to the pathology of SCC, and the importance of attentive management [4] . Treatments strategies can be broadly divided into lesionand field-directed. In patients with extensive photodamage, multiple lesions and field cancerization treatment of the field are considered most appropriate, given the importance of treating both clinically visible and subclinical lesions [3] . The choice of efficacy endpoints in AK clinical trials assessing field-directed therapies as well as their interpretation has been discussed previously by Wolf et al. [5] .
Traditionally, the count of the total number of clinically significant lesions in a selected area prior to and after a course of treatment has been commonly used [5] . Subclinical lesions which become visible during the course of therapy are also included as part of the efficacy assessment, however, making discrimination between inflammatory response of subclinical lesions and sun-damaged skin difficult. 
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